287 related articles for article (PubMed ID: 33616727)
1. Lessons from Pharmacovigilance: Pulmonary Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy.
Reese SW; Cone E; Marchese M; Garcia B; Chou W; Ayub A; Kilbridge K; Weinhouse G; Trinh QD
Lung; 2021 Apr; 199(2):199-211. PubMed ID: 33616727
[TBL] [Abstract][Full Text] [Related]
2. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Chen C; Wu B; Zhang C; Xu T
Int Immunopharmacol; 2021 Jun; 95():107498. PubMed ID: 33725634
[TBL] [Abstract][Full Text] [Related]
3. Renal toxicities in immune checkpoint inhibitors with or without chemotherapy: An observational, retrospective, pharmacovigilance study leveraging US FARES database.
Hu F; Zhai Y; Yuan L; Liang J; Xu J; Guo X; Zhou X; Lin Z; Sun J; Ye X; He J
Cancer Med; 2021 Dec; 10(24):8754-8762. PubMed ID: 34845857
[TBL] [Abstract][Full Text] [Related]
4. Neuroimmunological adverse events associated with immune checkpoint inhibitor: a retrospective, pharmacovigilance study using FAERS database.
Mikami T; Liaw B; Asada M; Niimura T; Zamami Y; Green-LaRoche D; Pai L; Levy M; Jeyapalan S
J Neurooncol; 2021 Mar; 152(1):135-144. PubMed ID: 33423151
[TBL] [Abstract][Full Text] [Related]
5. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
[TBL] [Abstract][Full Text] [Related]
6. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis.
Bomze D; Meirson T; Hasan Ali O; Goldman A; Flatz L; Habot-Wilner Z
Ocul Immunol Inflamm; 2022 Jan; 30(1):191-197. PubMed ID: 32749899
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
8. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Filippini DM; Gatti M; Di Martino V; Cavalieri S; Fusaroli M; Ardizzoni A; Raschi E; Licitra L
Int J Cancer; 2021 Aug; 149(3):675-683. PubMed ID: 33844854
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system.
Wang F; Wu X
J Clin Pharm Ther; 2022 Oct; 47(10):1576-1584. PubMed ID: 35726369
[TBL] [Abstract][Full Text] [Related]
10. Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhou X; Zheng Y; Zhao X; Xu X; Cao Y; He J
Front Endocrinol (Lausanne); 2021; 12():809063. PubMed ID: 35145482
[TBL] [Abstract][Full Text] [Related]
11. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary hypertension reported with immune checkpoint inhibitors: a pharmacovigilance study.
Palassin P; Maria ATJ; Ladhari C; Quantin X; Montani D; Bourdin A; Boissin C; Fesler P; Hillaire-Buys D; Guilpain P; Faillie JL
Cancer Immunol Immunother; 2022 Dec; 71(12):3093-3097. PubMed ID: 35616698
[TBL] [Abstract][Full Text] [Related]
13. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database.
Anquetil C; Salem JE; Lebrun-Vignes B; Touhami S; Desbois AC; Maalouf G; Domont F; Allenbach Y; Cacoub P; Bodaghi B; Saadoun D
J Autoimmun; 2020 Jul; 111():102454. PubMed ID: 32303423
[TBL] [Abstract][Full Text] [Related]
14. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
15. Hematological toxicities in immune checkpoint inhibitors: A pharmacovigilance study from 2014 to 2019.
Ye X; Hu F; Zhai Y; Qin Y; Xu J; Guo X; Zhuang Y; He J
Hematol Oncol; 2020 Oct; 38(4):565-575. PubMed ID: 32383782
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
17. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBaseď from 2010 to 2020.
Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
[TBL] [Abstract][Full Text] [Related]
18. Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.
Raschi E; Gatti M; Gelsomino F; Ardizzoni A; Poluzzi E; De Ponti F
Target Oncol; 2020 Aug; 15(4):449-466. PubMed ID: 32725437
[TBL] [Abstract][Full Text] [Related]
19. Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the Japanese Adverse Drug Event Report database.
Sato K; Mano T; Iwata A; Toda T
J Neurooncol; 2019 Oct; 145(1):1-9. PubMed ID: 31452071
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.
Bukamur H; Katz H; Alsharedi M; Alkrekshi A; Shweihat YR; Munn NJ
South Med J; 2020 Nov; 113(11):600-605. PubMed ID: 33140115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
